AllergyTalk Episode 41 - A Promising New Treatment for SCID!
Price: FREE for members and non-members
Speakers: Gerald Lee, MD, Stanley Fineman, MD and Timothy Chow, MD
Listeners can earn credit by completing the posttest questions
AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date onthe latest advances in the field of allergy and immunology.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this podcast, the participant should be able to:
1. Discuss racial and ethnic disparities in prescribing patterns of subcutaneous immunotherapy for allergic rhinitis.
2. Discuss the method of CRISPR base editing to cure severe combined immunodeficiency.
All relevant financial relationships with ineligible companies have been mitigated.
Gerald Lee, MD
No relevant financial relationships with ineligible companies to disclose
Stanley Fineman, MD
Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Timothy Chow, MD
No relevant financial relationships with ineligible companies to disclose
Available Credit
- 0.25 AMA PRA Category 1 Credit™
- 0.25 Attendance